GLP-2 Research

Rose BD, Kreuch D, Wu T, Horowitz M, Rayner CK, Page AJ et al.

Foods and beverages sweetened with non-nutritive sweeteners (NNSs) are increasingly common in modern diets and widely promoted as healthy alternatives to their sugar-sweetened counterparts, with attendant benefits for individuals with preclinical or clinical metabolic disease. Despite this positi...

Gupta R, Nainwal P, Padhi S, Srinivasan H

Czarnecki M, Baranowska-Bik A, Litwiniuk A, Kalisz M, Domańska A, Kurdyła A et al.

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by progressive cognitive decline, β-amyloid accumulation, tau pathology, oxidative stress, and neuroinflammation. Increasing evidence suggests that metabolic dysregulation may contribute to AD pathogenesis. G...

Posovszky C, de Laffolie J, Henning S, Ballauf A, Berrang J, Bildheim V et al.

Paediatric short bowel syndrome (SBS) with chronic intestinal failure (IF) is a rare, complex and potentially life-threatening condition. The main causes in children are necrotizing enterocolitis, volvulus, congenital malformations, and other enteropathies. The resulting reduced intestinal absorp...

Teso MV, Conley TE, Lal S

Chronic intestinal failure (CIF) is a rare condition characterized by inadequate intestinal absorption requiring long-term parenteral nutrition (PN). Given etiological shifts and expanding therapeutic options, we provide an updated review covering CIF definitions, epidemiology and multidisciplina...

Gao SN, Xu ZL, Huang XJ

Acute graft-versus-host disease (aGVHD) remains a severe complication following allogeneic hematopoietic stem cell transplantation, and traditional corticosteroid therapy often demonstrates limited efficacy. This review highlights the recent advances in cellular and targeted immunotherapies for a...

Astiarraga B, Rodriguez-Castellano A, Ceperuelo-Mallafré V, Marsal-Beltran A, Osuna-Prieto FJ, Vilanova N et al.

The study aims to characterize the secretion dynamics of glucagon-related peptides, including GLP-1, GIP, and GLP-2, across different stages of metabolic-associated steatotic liver disease (MASLD), while evaluating the impact of type 2 diabetes (T2D) on these hormonal responses. Thirty-four MASLD...

Zhang D, Wei Y, Zhu X, Zong L, Cui M, Li D et al.

Taishan Red Reishi Mushroom, also known as Taishan Ganoderma lucidum, is a medicinal and edible mushroom. Polysaccharides from Taishan Ganodermalucidum (GLP) represent its most significant bioactive component. This study aims to examine the structural characteristics of the GLP polysaccharide fra...

Nishina R, Hino S, Kato C, Nishimura N

Small intestinal villous atrophy, a frequent complication of cancer chemotherapy, impairs nutrient absorption and worsens participant quality of life. Although the glucagon-like peptide-2 (GLP-2) analog teduglutide can promote villus regeneration, its clinical application is limited. We hypothesi...

Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A

The gastrointestinal tract acts as an endocrine organ, releasing hormones that regulate glucose homeostasis, appetite, energy expenditure, and gastrointestinal motility. In type 2 diabetes (T2DM) and obesity, this finely tuned hormonal system is disrupted, contributing to metabolic dysfunction. T...

Wu K, Ren W, Xu B, Shen J, Xu K, Hu Y et al.

Glucagon-like peptide-2 (GLP-2) has been demonstrated to stimulate bone formation and increase bone mass. Conversely, aberrant expression of fibroblast growth factor 23 (FGF23), a crucial bone-derived hormone that regulates phosphate metabolism and mineralization, is implicated in the pathogenesi...

Maklad M, Osman M, Ismail M, Tajima T, Radhakrishnan K, Fujiki M et al.

Intestinal and multivisceral transplantation has evolved from an experimental to a life-saving procedure for children and adults with complications of gut failure (GF). Suboptimal long-term outcomes of transplant elicit recent advances in surgical and medical gut rehabilitation along with the int...

Greig G, Hay J, Valencia P, Boules M, Masior T

Intestinal failure-associated liver disease occurs in 20% to 30% of patients with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide is a glucagon-like peptide-2 (GLP-2) analog in clinical development for the treatment of patients with SBS-IF. This study assessed the potential for ...

Vanuytsel T, Joly F, Iyer K, Bolognani F, Mitchell G, Berger S et al.

Short bowel syndrome with intestinal failure (SBS-IF) requires lengthy parenteral support (PS) infusions to maintain nutrition and hydration, and may also involve treatment with glucagon-like peptide 2 (GLP-2) analog injections. SBS-IF and its treatment have significant health-related quality-of-...

Sørum NE, Magnussen T, Hansen NL, Nielsen CK, Holst JJ, Hartmann B et al.

Despite evidence of possible glucagonotropic effects, the role of the gut hormone glucagon-like peptide 2 (GLP-2) in glucose metabolism is unclear.This work aimed to evaluate the effect of exogenous GLP-2 on plasma glucagon levels during hypoglycemia, euglycemia, and hyperglycemia in healthy male...

Yang-Jensen SK, Choi BS, Nägele NS, Pærregaard SI, Neven K, Savickas V et al.

There is an urgent need for sustainable protein sources to meet rising global nutritional demands. Here, we show that a commercially scalable microbial lysate from Methylococcus capsulatus Bath (McB), used as a dietary protein, orchestrates host-diet-microbe interactions that protect against gast...

Irfan Z, Halder J, Giri S, Molla EA, Khanam S

Type 2 diabetes mellitus is associated with gut dysbiosis, decreased microbial diversity, short-chain fatty acid synthesis, and altered GLP secretion, which are crucial for intestinal integrity, insulin sensitivity, and postprandial glucose control. Evidence from peer-reviewed mechanistic studies...

Puig R, Rodríguez-Peña MM, Hernández-Montoliu L, Astiarraga B, Martínez E, Balibrea JM et al.

This study aims to assess the impact of insulin resistance (IR) on gut microbiota (GM) composition, incretin responses, and metabolic outcomes following sleeve gastrectomy (SG) in people with severe obesity who do not have diabetes.A prospective single-center study encompassed patients with sever...

Gerlach PA, Gadgaard S, Madsen JS, Lindquist P, Lorente JS, Faas F et al.

The glucagon-like peptide-2 receptor (GLP-2R) is recognized as a potential target for the treatment of obesity and type 2 diabetes (T2D). Yet, the impact and mechanism of GLP-2R activation on these metabolic traits remain unclear in humans.We conducted in vitro pharmacological characterization of...

Auernhammer CJ, Wang K, Maccio U, Knösel T, Hungbauer MP, Schilbach K et al.

Precision medicine has transformed many areas in oncology. However, it remains largely unexplored in metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), where there is a need for further innovative therapies.To evaluate individual tumor responses to different agents, we have es...